Ginkgo Bioworks Holdings, Inc. Class A (DNA)
DNA moved a median of +0.07% 30 minutes after news, and -0.25% by the close. How DNA actually reacts to news — the realized, point-in-time move the market made, measured across 907 labeled events over the last three years with zero look-ahead.
DNA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 906 |
| 30-min | +0.07% | 51% | 906 |
| 60-min | -0.07% | 46% | 906 |
| to close | -0.25% | 47% | 904 |
| Middle 50% of DNA reactions | -1.20% to +1.28% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 907 |
Half of all Ginkgo Bioworks Holdings, Inc. Class A news events land between -1.20% and +1.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DNA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 22 | -1.83% | 41% | -4.09% |
| Rating reiterations | 16 | -0.39% | 38% | -1.31% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how DNA ranks against every other measured name →
That’s how DNA usually reacts — get an email when it moves on news →Email me when DNA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DNA's baseline. Nothing else.
Recent DNA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop | Press release | PR Newswire | +1.19% | +3.85% | |
| Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program | Press release | Business Wire | -0.34% | +10.54% | |
| Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium | Press release | Business Wire | +4.28% | +13.47% | |
| Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data | Press release | Business Wire | +1.74% | -1.88% | |
| Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines | Press release | Business Wire | -0.60% | +1.19% | |
| Form 10-Q Ginkgo Bioworks Holdings For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -8.24% | -4.09% | |
| Form 8-K Ginkgo Bioworks Holdings For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -4.82% | |
| Form 8-K Ginkgo Bioworks Holdings For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | -0.61% | |
| Form 8-K Ginkgo Bioworks Holdings For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +0.12% | |
| Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery | Press release | PR Newswire | -0.46% | -0.80% | |
| Form 10-Q Ginkgo Bioworks Holdings For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.65% | +3.72% | |
| Form 8-K Ginkgo Bioworks Holdings For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +4.65% | +3.72% | |
| Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Press release | PR Newswire | +4.65% | +3.72% | |
| Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation | Press release | PR Newswire | +1.73% | +12.35% | |
| Form ARS Ginkgo Bioworks Holdings For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.73% | +12.35% | |
| Form DEF 14A Ginkgo Bioworks Holdings For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +1.73% | +12.35% | |
| Form DEFA14A Ginkgo Bioworks Holdings | SEC filing · Form DEFA14A | SEC EDGAR | +1.73% | +12.35% | |
| Form 8-K Ginkgo Bioworks Holdings For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | -1.78% | -6.01% | |
| Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure | Press release | PR Newswire | +1.53% | +8.13% | |
| Form 8-K Ginkgo Bioworks Holdings For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.65% | -16.46% | |
| Form 10-K Ginkgo Bioworks Holdings For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.65% | -16.46% | |
| Form 8-K Ginkgo Bioworks Holdings For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.65% | -16.46% | |
| Form S-8 Ginkgo Bioworks Holdings | SEC filing · Form S-8 | SEC EDGAR | -2.65% | -16.46% | |
| Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business | Press release | PR Newswire | -2.65% | -16.46% | |
| Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation | Press release | PR Newswire | +0.11% | +9.24% | |
| Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products | Press release | PR Newswire | +0.85% | +1.13% | |
| Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark | Press release | PR Newswire | +5.03% | +3.42% | |
| Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +1.44% | -1.13% | |
| Form 8-K Ginkgo Bioworks Holdings For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +3.24% | |
| Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach | Press release | PR Newswire | +0.22% | -1.35% | |
| Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment | Press release | PR Newswire | +2.54% | -0.24% | |
| Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety | Press release | PR Newswire | +1.62% | +2.46% | |
| Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High-Throughput Phenotyping Platform for DOE's M2PC | Press release | PR Newswire | -3.48% | -7.04% | |
| STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy | Press release | PR Newswire | -0.23% | +3.80% | |
| Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health | Press release | PR Newswire | +0.65% | +2.49% | |
| Form 10-Q Ginkgo Bioworks Holdings For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.72% | -13.02% | |
| Form 8-K Ginkgo Bioworks Holdings For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -2.72% | -13.02% | |
| Ginkgo Bioworks Reports Third Quarter 2025 Financial Results | Press release | PR Newswire | -2.72% | -13.02% | |
| Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium | Press release | PR Newswire | -1.12% | -0.85% | |
| Ginkgo Bioworks and Bayer Extend Multi-Year Strategic Partnership to Accelerate Next Generation Biological Solutions for Agriculture | Press release | PR Newswire | +0.41% | +7.09% | |
| Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation | Press release | PR Newswire | +0.41% | +7.09% | |
| Augment.us Evolves from Sourcing Tool to Candidate Engagement Driver Across All Career Levels | Press release | PR Web | -0.56% | +0.70% | |
| Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program | Press release | PR Newswire | -0.92% | +2.17% | |
| Form 8-K Ginkgo Bioworks Holdings For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | +0.36% | |
| Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium | Press release | Business Wire | +0.89% | +4.38% | |
| Form 8-K Ginkgo Bioworks Holdings For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | -8.32% | |
| Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions | Press release | PR Newswire | +0.87% | -8.32% | |
| Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Partner to Deploy AI-driven Lab-in-the-loop Workflows Across the Biopharma Industry | Press release | PR Newswire | +0.13% | -3.58% | |
| Form EFFECT Ginkgo Bioworks Holdings | SEC filing · Form EFFECT | SEC EDGAR | -1.65% | +1.39% | |
| Ginkgo Automation Appoints Brian?O'Sullivan as Head of Commercial to Accelerate External Growth | Press release | PR Newswire | +0.45% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DNA section they belong to.
Where else DNA is measured.
DNA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ginkgo Bioworks Holdings, Inc. Class A's median reaction calculated?
Every labeled DNA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 907 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of DNA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DNA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.